PubMed

Incretin-based therapies: viewpoints on the way to consensus.

Nauck MA, Vilsbøll T, Gallwitz B, Garber A, Madsbad S.

Diabetes Care. 2009 Nov;32 Suppl 2:S223-31. No abstract available. PMID: 19875556 [PubMed - in process]Related articles

Self-monitoring of blood glucose in diabetes mellitus: arguments for an individualized approach.

Nauck MA, El-Ouaghlidi A, Vardarli I.

Dtsch Arztebl Int. 2009 Sep;106(37):587-94. Epub 2009 Sep 11.PMID: 19890425 [PubMed - in process]Related articlesFree article

For insulinomas, no place to hide.

Nauck MA, Meier JJ.

J Clin Endocrinol Metab. 2009 Nov;94(11):4125-6. No abstract available. PMID: 19890029 [PubMed - in process]Related articles

Incretin hormones and their therapeutic potential in patients with type 2 diabetes. Preface.

Nauck MA.

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):vii. No abstract available. PMID: 19748058 [PubMed - in process]Related articles

Unraveling the science of incretin biology.

Nauck MA.

Eur J Intern Med. 2009 Jul;20 Suppl 2:S303-8. Epub 2009 Jun 21. Review.PMID: 19580949 [PubMed - indexed for MEDLINE]Related articles

Unraveling the science of incretin biology.

Nauck MA.

Am J Med. 2009 Jun;122(6 Suppl):S3-S10. Review.PMID: 19464426 [PubMed - indexed for MEDLINE]Related articles

Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.

Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R.

Diabetes Care. 2009 Jul;32(7):1237-43. Epub 2009 Apr 14.PMID: 19366970 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.

Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 008 Group.

Int J Clin Pract. 2009 Jan;63(1):46-55.PMID: 19125992 [PubMed - indexed for MEDLINE]Related articles

Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?

Meier JJ, Nauck MA.

Nat Clin Pract Endocrinol Metab. 2008 Nov;4(11):606-7. Epub 2008 Aug 26. No abstract available. PMID: 18725906 [PubMed - indexed for MEDLINE]Related articles

Excess glycaemic excursions after an oral glucose tolerance test compared with a mixed meal challenge and self-measured home glucose profiles: is the OGTT a valid predictor of postprandial hyperglycaemia and vice versa?

Meier JJ, Baller B, Menge BA, Gallwitz B, Schmidt WE, Nauck MA.

Diabetes Obes Metab. 2009 Mar;11(3):213-22. Epub 2008 Jun 16.PMID: 18564177 [PubMed - indexed for MEDLINE]Related articles

Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?

Van Gaal LF, Gutkin SW, Nauck MA.

Eur J Endocrinol. 2008 Jun;158(6):773-84. Epub 2008 Mar 5. Review.PMID: 18322302 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparison of pancreas-transplanted type 1 diabetic patients with portal-venous versus systemic-venous graft drainage: impact on glucose regulatory hormones and the growth hormone/insulin-like growth factor-I axis.

Frystyk J, Ritzel RA, Maubach J, Büsing M, Lück R, Klempnauer J, Schmiegel W, Nauck MA.

J Clin Endocrinol Metab. 2008 May;93(5):1758-66. Epub 2008 Mar 4.PMID: 18319317 [PubMed - indexed for MEDLINE]Related articlesFree article

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.

Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ.

Diabetes. 2008 Mar;57(3):678-87. Epub 2007 Dec 5.PMID: 18057091 [PubMed - indexed for MEDLINE]Related articlesFree article

The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms.

Nauck MA, Meier JJ.

Diabetologia. 2007 Dec;50(12):2413-6. No abstract available. PMID: 17898988 [PubMed - indexed for MEDLINE]Related articles

Hemofiltration of recombinant hirudin by different hemodialyzer membranes: implications for clinical use.

Benz K, Nauck MA, Böhler J, Fischer KG.

Clin J Am Soc Nephrol. 2007 May;2(3):470-6. Epub 2007 Mar 21.PMID: 17699453 [PubMed - indexed for MEDLINE]Related articlesFree article

The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D, Nauck MA.

J Clin Endocrinol Metab. 2007 Nov;92(11):4165-71. Epub 2007 Aug 14.PMID: 17698900 [PubMed - indexed for MEDLINE]Related articlesFree article

Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans.

Meier JJ, Holst JJ, Schmidt WE, Nauck MA.

Am J Physiol Endocrinol Metab. 2007 Sep;293(3):E849-56. Epub 2007 Jul 3.PMID: 17609256 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes.

Maggs D, MacDonald I, Nauck MA.

Diabetes Obes Metab. 2008 Jan;10(1):18-33. Epub 2007 May 8. Review.PMID: 17490426 [PubMed - indexed for MEDLINE]Related articles

Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects.

Meier JJ, Deacon CF, Schmidt WE, Holst JJ, Nauck MA.

Diabetologia. 2007 Apr;50(4):806-13. Epub 2007 Feb 16.PMID: 17334652 [PubMed - indexed for MEDLINE]Related articles

Preserved GLP-1 effects in a diabetic patient with Cushing's disease.

Ritzel RA, Kleine N, Holst JJ, Willms B, Schmiegel W, Nauck MA.

Exp Clin Endocrinol Diabetes. 2007 Feb;115(2):146-50.PMID: 17318778 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group.

Diabetes Obes Metab. 2007 Mar;9(2):194-205.PMID: 17300595 [PubMed - indexed for MEDLINE]Related articles

Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung.

Nauck MA, Reinecke M, Perren A, Frystyk J, Berishvili G, Zwimpfer C, Figge AM, Flyvbjerg A, Lankisch PG, Blum WF, Klöppel G, Schmiegel W, Zapf J.

J Clin Endocrinol Metab. 2007 May;92(5):1600-5. Epub 2007 Feb 13.PMID: 17299065 [PubMed - indexed for MEDLINE]Related articlesFree article

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M.

Diabetologia. 2007 Feb;50(2):259-67. Epub 2006 Dec 8.PMID: 17160407 [PubMed - indexed for MEDLINE]Related articles

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

Drucker DJ, Nauck MA.

Lancet. 2006 Nov 11;368(9548):1696-705. Review.PMID: 17098089 [PubMed - indexed for MEDLINE]Related articles

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.

Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J; NN2211-1499 Study Group.

Exp Clin Endocrinol Diabetes. 2006 Sep;114(8):417-23.PMID: 17039422 [PubMed - indexed for MEDLINE]Related articles

Incretins and the development of type 2 diabetes.

Meier JJ, Nauck MA.

Curr Diab Rep. 2006 Jun;6(3):194-201. Review.PMID: 16898571 [PubMed - indexed for MEDLINE]Related articles

Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls.

Meier JJ, Nauck MA, Kask B, Holst JJ, Deacon CF, Schmidt WE, Gallwitz B.

World J Gastroenterol. 2006 Mar 28;12(12):1874-80.PMID: 16609993 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.

Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, Nauck MA, Wishart J, Horowitz M, Feinle-Bisset C.

J Clin Endocrinol Metab. 2006 May;91(5):1916-23. Epub 2006 Feb 21.PMID: 16492694 [PubMed - indexed for MEDLINE]Related articlesFree article

Comment to: Patti ME, McMahon G, Mun EC et al. (2005) Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 48:2236-2240.

Meier JJ, Nauck MA, Butler PC.

Diabetologia. 2006 Mar;49(3):607-8; author reply 609-10. Epub 2006 Jan 31. No abstract available. PMID: 16450091 [PubMed - indexed for MEDLINE]Related articles

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans.

Meier JJ, Gethmann A, Götze O, Gallwitz B, Holst JJ, Schmidt WE, Nauck MA.

Diabetologia. 2006 Mar;49(3):452-8. Epub 2006 Jan 31.PMID: 16447057 [PubMed - indexed for MEDLINE]Related articles

To be or not to be--an incretin or enterogastrone?

Horowitz M, Nauck MA.

Gut. 2006 Feb;55(2):148-50.PMID: 16407380 [PubMed - indexed for MEDLINE]Related articlesFree article

The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.

Meier JJ, Gethmann A, Nauck MA, Götze O, Schmitz F, Deacon CF, Gallwitz B, Schmidt WE, Holst JJ.

Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1118-23. Epub 2006 Jan 10.PMID: 16403774 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.

Meier JJ, Nauck MA, Pott A, Heinze K, Goetze O, Bulut K, Schmidt WE, Gallwitz B, Holst JJ.

Gastroenterology. 2006 Jan;130(1):44-54.PMID: 16401467 [PubMed - indexed for MEDLINE]Related articles

Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes: the Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA).

Meier JJ, Deifuss S, Klamann A, Launhardt V, Schmiegel WH, Nauck MA.

Diabetes Care. 2005 Oct;28(10):2551-3. No abstract available. PMID: 16186299 [PubMed - indexed for MEDLINE]Related articlesFree article

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.

Fehse F, Trautmann M, Holst JJ, Halseth AE, Nanayakkara N, Nielsen LL, Fineman MS, Kim DD, Nauck MA.

J Clin Endocrinol Metab. 2005 Nov;90(11):5991-7. Epub 2005 Sep 6.PMID: 16144950 [PubMed - indexed for MEDLINE]Related articlesFree article

Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.

Meier JJ, Gallwitz B, Askenas M, Vollmer K, Deacon CF, Holst JJ, Schmidt WE, Nauck MA.

Diabetologia. 2005 Sep;48(9):1872-81. Epub 2005 Jul 12.PMID: 16010522 [PubMed - indexed for MEDLINE]Related articles

Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.

Meier JJ, Kemmeries G, Holst JJ, Nauck MA.

Diabetes. 2005 Jul;54(7):2212-8.PMID: 15983224 [PubMed - indexed for MEDLINE]Related articlesFree article

[Therapy with oral antidiabetic agents -- special considerations in the case of coronary heart disease]

Nauck MA, Matthaei S.

Dtsch Med Wochenschr. 2005 Apr 29;130(17):1091-6. Review. German. No abstract available. PMID: 15841424 [PubMed - indexed for MEDLINE]Related articles

alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.

Hücking K, Kostic Z, Pox C, Ritzel R, Holst JJ, Schmiegel W, Nauck MA.

Diabet Med. 2005 Apr;22(4):470-6.PMID: 15787675 [PubMed - indexed for MEDLINE]Related articles

Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

Nauck MA, Meier JJ.

Regul Pept. 2005 Jun 15;128(2):135-48. Review.PMID: 15780433 [PubMed - indexed for MEDLINE]Related articles

The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.

Nauck MA, El-Ouaghlidi A.

Diabetologia. 2005 Apr;48(4):608-11. Epub 2005 Mar 11. No abstract available. PMID: 15761719 [PubMed - indexed for MEDLINE]Related articles

Glucagon-like peptide 1(GLP-1) in biology and pathology.

Meier JJ, Nauck MA.

Diabetes Metab Res Rev. 2005 Mar-Apr;21(2):91-117. Review.PMID: 15759282 [PubMed - indexed for MEDLINE]Related articles

GIP as a potential therapeutic agent?

Meier JJ, Nauck MA.

Horm Metab Res. 2004 Nov-Dec;36(11-12):859-66. Review.PMID: 15655720 [PubMed - indexed for MEDLINE]Related articles

Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.

Nauck MA.

Horm Metab Res. 2004 Nov-Dec;36(11-12):852-8. Review.PMID: 15655719 [PubMed - indexed for MEDLINE]Related articles

Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.

Meier JJ, Gallwitz B, Kask B, Deacon CF, Holst JJ, Schmidt WE, Nauck MA.

Diabetes. 2004 Dec;53 Suppl 3:S220-4.PMID: 15561915 [PubMed - indexed for MEDLINE]Related articlesFree article

Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.

Nauck MA, Baller B, Meier JJ.

Diabetes. 2004 Dec;53 Suppl 3:S190-6. Review.PMID: 15561910 [PubMed - indexed for MEDLINE]Related articlesFree article

Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide.

Meier JJ, Nauck MA.

Best Pract Res Clin Endocrinol Metab. 2004 Dec;18(4):587-606. Review.PMID: 15533777 [PubMed - indexed for MEDLINE]Related articles

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.

Nauck MA, El-Ouaghlidi A, Gabrys B, Hücking K, Holst JJ, Deacon CF, Gallwitz B, Schmidt WE, Meier JJ.

Regul Pept. 2004 Nov 15;122(3):209-17.PMID: 15491793 [PubMed - indexed for MEDLINE]Related articles

The potential role of glucagon-like peptide 1 in diabetes.

Meier JJ, Nauck MA.

Curr Opin Investig Drugs. 2004 Apr;5(4):402-10. Review.PMID: 15134281 [PubMed - indexed for MEDLINE]Related articles

Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes.

Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck MA, Holst JJ, Schmidt WE, Gallwitz B.

Crit Care Med. 2004 Mar;32(3):848-51.PMID: 15090972 [PubMed - indexed for MEDLINE]Related articles